Merus N.V. Shareholders to Vote on Genmab Acquisition Offer

New activity is brewing for Merus ( (MRUS) ). The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareholder vote. This form gives shareholders all the information they need to develop an informed vote. Read on to learn more about the proposed company action.

On December 9, 2025, Merus N.V. will hold an Extraordinary General Meeting of Shareholders to discuss and vote on the proposed acquisition by Genmab Holding II B.V., a subsidiary of Genmab A/S. Genmab has offered to purchase all outstanding common shares of Merus for $97.00 per share in cash. The Merus Board has unanimously determined that the transaction is in the best interests of the company and its stakeholders. The acquisition is expected to impact Merus’ operations and industry positioning significantly, aligning with the interests of shareholders and employees.

The most recent analyst rating on (MRUS) stock is a Hold with a $96.00 price target. To see the full list of analyst forecasts on Merus stock, see the MRUS Stock Forecast page.

Spark’s Take on MRUS Stock

According to Spark, TipRanks’ AI Analyst, MRUS is a Neutral.

Merus’s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue and substantial losses. While technical analysis indicates strong upward momentum, the overbought signals suggest caution. The negative P/E ratio further reflects the company’s financial struggles, limiting its valuation appeal.

To see Spark’s full report on MRUS stock, click here.

More about Merus

Merus N.V. is a public limited liability company based in the Netherlands, operating in the biotechnology industry. The company focuses on developing innovative therapeutics for cancer treatment.

Average Trading Volume: 2,172,620

Technical Sentiment Signal: Buy

Current Market Cap: $7.24B

For an in-depth examination of MRUS stock, go to TipRanks’ Overview page.